Natera To Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis From CIRCULATE-Japan Study
Portfolio Pulse from Benzinga Newsdesk
Natera, Inc. (NASDAQ:NTRA) will present new data on its molecular residual disease (MRD) test, Signatera, at the 2023 European Society for Medical Oncology (ESMO) Congress. The data includes an updated analysis of over 2,000 patients from the GALAXY observational arm of the CIRCULATE-Japan trial, one of the largest studies of MRD testing in resectable colorectal cancer. Other presentations will highlight new Signatera data in various types of cancer.
October 16, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's presentation of new data on its MRD test, Signatera, at the ESMO 2023 Congress could potentially boost investor confidence in the company's product and its application in various types of cancer.
The presentation of new data on Natera's MRD test, Signatera, at a major oncology congress could potentially boost the product's credibility and visibility in the medical community. This could lead to increased adoption of the test, potentially driving revenue growth for Natera.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100